Kidney disease treatment & trial finder
Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.
For information only — not medical advice. Always talk to your nephrologist.
Kidney treatment is advancing fast
17 FDA-approved therapies since 2018 — 8 in the last two years — plus 3 trials enrolling now.
New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.
Treatment Options for Your Diagnosis
Foundational care
Start hereStandard care combines immunosuppression (steroids plus mycophenolate or cyclophosphamide) with an ACE inhibitor or ARB and blood-pressure control. Your nephrologist and rheumatologist usually start here.
These are newer and recently approved therapies for Lupus nephritis — not the full standard of care. Ask your care team whether any fit your situation.
Calcineurin inhibitor
Evidence: Complete renal response 41% vs 23% at 1 year; benefit sustained through 3 years.
Source: FDA prescribing information; AURORA 1, Lancet 2021Verified 2026-07-18
BLyS-specific inhibitor (anti-BAFF)
Evidence: Complete renal response 30% vs 20% with standard therapy alone.
Source: FDA prescribing information; BLISS-LN, NEJM 2020Verified 2026-07-18
Type II anti-CD20 B-cell depleting antibody
Evidence: Complete renal response 46% vs 33% added to standard therapy in the Phase 3 REGENCY trial.
Source: FDA prescribing information (Gazyva); REGENCY, NEJM 2025Verified 2026-07-18
Clinical Trials Related to Your Diagnosis
Actively enrolling studies related to Lupus nephritis. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.
Enrolling adolescents with active class III/IV lupus nephritis (plus younger children for safety) — extending the recently approved adult therapy to younger patients.
Eligibility is determined by the study team and your nephrologist.
View the Obinutuzumab in adolescents on ClinicalTrials.govSource: Extends REGENCY (NEJM 2025); RocheVerified 2026-07-18
For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.
Conditions covered
Jump straight to treatments and enrolling trials for a specific kidney diagnosis.
Manage your whole kidney journey
Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.
Get started free